Ask anything about research
Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Hot Research Today
Papers from every journal, all in one place
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
✨ Key Finding: Discontinuation of beta-blockers beyond the first year after a myocardial infarction was noninferior to continuation regarding death, recurrent MI, or heart failure hospitalization.
At subsequent visits, it’s always an opportunity to revisit [and ask] can we reduce this pill burden? This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-bl...
Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study
✨ Key Finding: Sotatercept significantly reduced pulmonary vascular resistance by 1.02 Wood units (0.3 mg/kg) and 0.75 Wood units (0.7 mg/kg) compared to placebo at 24 weeks in patients with CpcPH-HFpEF.
Similar to PAH trials, the benefits of sotatercept transcend the relatively modest reductions in resting PVR and highlight the importance of targeting inflammation, cell proliferation and endothelial function in HFpEF. As the biology of ligand traps evolves, sotatercept marks the first step in leveraging the power of signaling networks to reverse fibrosis and cellular hypertrophy. Notably, the CADENCE trial emphasizes the importance of targeting underlying biologic mechanisms responsible for disease, versus focusing solely on improving hemodynamic parameters.
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials
✨ Key Finding: A hybrid AI adjudication approach using 30% human review correctly classified 95.6% of cardiovascular endpoints and replicated the primary treatment effect (HR 1.04 vs human HR 1.02).
Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial
Randomized controlled trial shows improved IRA patency in STEMI patients with heparin pretreatment, suggesting effective intervention.
2026 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association
The scientific statement provides guidance on heart-healthy dietary patterns for reducing cardiovascular disease risk.
“参考文献： https://t.co/UFBkLaUJcr”
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks
✨ Key Takeaway: Abbreviated or de-escalated dual antiplatelet therapy reduces bleeding and improves net clinical outcomes in the 20-40% of acute coronary syndrome patients classified as high bleeding risk.
Pregnancy-Associated Spontaneous Coronary Artery Dissection
✨ Key Finding: Women with pregnancy-associated spontaneous coronary artery dissection have a more severe phenotype than non-pregnancy cases, with higher STEMI incidence (18.6% vs 5.5%) and less LVEF recovery.
Serum Neurofilament Light Chain and Cardiovascular Outcomes in Patients With Atrial Fibrillation
✨ Key Finding: Elevated serum neurofilament light chain in patients with atrial fibrillation was associated with increased major vascular events (aHR 1.35 per doubling of concentration).
Atrial fibrillation density as a biomarker for ischaemic stroke risk prediction
✨ Key Finding: Atrial fibrillation density showed a dose-response relationship with 1-year ischemic stroke risk (RR 1.75; 95% CI 1.25-2.44), independent of overall AF burden.
Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial
✨ Key Finding: Extensive electro-anatomic-guided ablation achieved the lowest 36-month rate of cardiovascular events (17.0%) and highest sinus rhythm maintenance (62.0%) in patients with persistent AF and HF.